The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease
Open accessAbstract
Diabetes is now a pandemic disease. Moreover, a large number of people with prediabetes are at risk for developing frank diabetes worldwide. Both type 1 and type 2 diabetes increase the risk of atherosclerotic cardiovascular disease (CVD). Even with statin treatment to lower LDL cholesterol, patients with diabetes have a high residual CVD risk. Factors mediating the residual risk are incompletely characterized. An attractive hypothesis is that remnant lipoprotein particles (RLPs), derived by lipolysis from VLDL and chylomicrons, contribute to this residual risk. RLPs constitute a heterogeneous population of lipoprotein particles, varying markedly in size and composition. Although a universally accepted definition is lacking, for the purpose of this review we define RLPs as postlipolytic partially triglyceride-depleted particles derived from chylomicrons and VLDL that are relatively enriched in cholesteryl esters and apolipoprotein (apo)E. RLPs derived from chylomicrons contain apoB48, while those derived from VLDL contain apoB100. Clarity as to the role of RLPs in CVD risk is hampered by lack of a widely accepted definition and a paucity of adequate methods for their accurate and precise quantification. New specific methods for RLP quantification would greatly improve our understanding of their biology and role in promoting atherosclerosis in diabetes and other disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“elevated plasma TG levels (with the accumulation of TRL and remnant particles) are related not only to subclinical atherosclerosis and vascular inflammation independently of LDL-C in statin-naïve, apparently healthy subjects”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At moderately elevated plasma TG levels, there is increased secretion of large TG-enriched VLDL and chylomicrons from the liver and small intestine that, when combined with suboptimal LpL action in obesity, insulin resistance, and/or diabetes mellitus, results in remnant accumulation.36”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The absence of lipolysis (i.e. complete LPL deficiency) results in the extreme elevation of large ‘nascent’ TRL without any concomitant increase in remnants;36,67,68 here, pancreatitis rather than ASCVD is the major risk.”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On a per particle basis, cholesterol-rich remnant particles are more potent inducers of macrophage foam cells than LDL and do not need structural modification to trigger uptake.36,93,141”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“but also equally to residual cardiovascular risk among statin-treated patients, especially those with diabetes mellitus.2,20,36–38”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
The Metabolic Basis of Inherited Disease
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-389_2 · Cited by 3,983
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 3×
“Furthermore, clinical trials of fibrates and n-3 fatty acids (polyunsaturated fatty acids, also often referred to as fish oils) have, with the exception of REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) and JELIS (Japan EPA Lipid Intervention Study), been mostly negative for CVD…”
BackgroundAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335 · cited 1×
“A recent new classification system of T2DM, based on different patient characteristics and risk of diabetes complications, divides adults into five different clusters of diabetes (3).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 1×
“Abundant epidemiological evidence associated triglyceride levels with CVD risk (11,12), although the risk was often attenuated when adjusted for potential confounders, such as HDL-C (13).”
BackgroundTriglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citationAtherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701 · cited 1×
“Despite decades of experimental data linking RLPs to atherogenesis in animal models and humans (70), the impact of RLPs as causal mediators in CVD associated with hypertriglyceridemia in patients with T2DM is still uncertain.”
BackgroundChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationPathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708 · cited 1×
“LDL-C concentrations are normal or only slightly elevated, but the LDL particles are characteristically small and dense with triglyceride enrichment (55).”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“A key early observation was that a null mutation in APOC3, the gene encoding apoC-III (apoC3), which acts in part by inhibiting LPL, associated with reduced triglyceride levels and reduced CVD risk in an Amish population (15).”
BackgroundHyperlipidemia in Coronary Heart Disease I. LIPID LEVELS IN 500 SURVIVORS OF MYOCARDIAL INFARCTION
Goldstein, J. L., Hazzard, W. R., Schrott, H. G., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107331 · Cited by 622 · cited 1×
“More than 40 years ago studies of familial forms of hypertriglyceridemia linked elevated triglyceride levels to an increased risk of CVD (10).”
BackgroundSandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608 · cited 6×
“Elevated plasma triglycerides can be due to increased triglyceride production, decreased lipolysis of triglycerides, and/or reduced clearance of TRLs (7).”
BackgroundInfluentialYahagi, K., Kolodgie, F. D., Lutter, C., Mori, H., Romero, M. E., Finn, A. V., & Virmani, R. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.306256 · Cited by 573 · cited 2×
“Loss-of-function mutations in ANGPTL3, another gene in the angiopoietinlike protein family, is associated with reduced CVD risk and lower triglyceride levels as well as lower levels of LDL-C and HDL-C (familial combined hypolipidemia) (4).”
BackgroundCardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies
Mazzone, T., Chait, A., & Plutzky, J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60768-0 · Cited by 545 · cited 1×
“, obese patients with T2DM), RLPs have been claimed to be a risk factor for CVD distinct from LDL (6,50,51).”
BackgroundSelf-citationHavel, R. J., Kane, J. P., & Kashyap, M. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107171 · Cited by 528 · cited 1×
“The mechanism for these changes appears to be the reduction in volume and surface area of the nascent chylomicrons and VLDL by LPL resulting in the preferential movement of apoCs to HDL as well as the direct addition of apoE that is secreted by the liver (23,24).”
Backgroundde Ferranti, S. D., de Boer, I. H., Fonseca, V., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000034 · Cited by 503 · cited 1×
“Diabetes and Residual Cardiovascular Disease Risk Both type 1 (T1DM) and type 2 (T2DM) diabetes mellitus increase the risk of cardiovascular disease (CVD) (1,2).”
Backgroundde Ferranti, S. D., de Boer, I. H., Fonseca, V., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1720 · Cited by 433
Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling
Nicholls, S. J., Tuzcu, E. M., Kalidindi, S., Wolski, K., Moon, K.-W., Sipahi, I., Schoenhagen, P., & Nissen, S. E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.051 · Cited by 349 · cited 1×
“Moreover, after cholesterol reduction, intravascular ultrasound studies show less regression of lesions in people with diabetes (5).”
BackgroundZILVERSMIT, D. B. (1973) · Circulation Research · doi:10.1161/01.res.33.6.633 · Cited by 338 · cited 2×
“Already in the early 1970s Zilversmit proposed that TRLs and remnants accumulate at arterial foci in proportion to the local concentrations of sulfated polysaccharides (21).”
BackgroundMjos, O. D., Faergeman, O., Hamilton, R. L., & Havel, R. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108130 · Cited by 322 · cited 1×
“The mechanism for these changes appears to be the reduction in volume and surface area of the nascent chylomicrons and VLDL by LPL resulting in the preferential movement of apoCs to HDL as well as the direct addition of apoE that is secreted by the liver (23,24).”
BackgroundLipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis
Ginsberg, H. N. (1991) · Diabetes Care · doi:10.2337/diacare.14.9.839 · Cited by 277 · cited 9×
“The hallmark of dyslipidemia in T2MD is high plasma triglycerides and low HDL-C.”
BackgroundInfluentialSelf-citationApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Gordts, P. L. S. M., Nock, R., Son, N.-H., Ramms, B., Lew, I., Gonzales, J. C., Thacker, B. E., Basu, D., Lee, R. G., Mullick, A. E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86610 · Cited by 274 · cited 12×
“Already in the early 1970s Zilversmit proposed that TRLs and remnants accumulate at arterial foci in proportion to the local concentrations of sulfated polysaccharides (21).”
BackgroundInfluentialSelf-citationThe biochemical, clinical, and genetic features of type III hyperlipoproteinemia.
MORGANROTH, J., LEVY, R. I., & FREDRICKSON, D. S. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-2-158 · Cited by 260 · cited 2×
“The high prevalence of premature coronary artery disease (43,44) in remnant removal disease is strongly supportive of a direct role for RLPs in atherogenesis.”
BackgroundSchneeman, B. O., Kotite, L., Todd, K. M., & Havel, R. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.2069 · Cited by 255 · cited 1×
“As a result, although apoB48containing chylomicrons and their remnants contribute the large majority of the rise of triglycerides in the postprandial state, TRLs containing apoB100 account for most of the increase in total apoB lipoproteins observed postprandially (22).”
BackgroundKrauss, R., Williams, P., Brensike, J., Detre, K., Lindgren, F., Kelsey, S., Vranizan, K., & Levy, R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92734-6 · Cited by 253 · cited 1×
“, obese patients with T2DM), RLPs have been claimed to be a risk factor for CVD distinct from LDL (6,50,51).”
BackgroundRedgrave, T. G., & Small, D. M. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109435 · Cited by 237
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237 · cited 2×
“Thus, genes involved in TRL metabolism such as lipoprotein lipase (LPL) and genes that control LPL’s activity appear to strongly associate with CVD risk (14).”
BackgroundDirect Determination of Lipoprotein Particle Sizes and Concentrations by Ion Mobility Analysis
Caulfield, M. P., Li, S., Lee, G., Blanche, P. J., Salameh, W. A., Benner, W. H., Reitz, R. E., & Krauss, R. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.100586 · Cited by 227 · cited 2×
“The differential ion mobility analysis method is based on the principle that particles of a given size and charge behave in a predictable manner when carried in a laminar flow of air and subjected to an electric field (39).”
BackgroundMethodStanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L., & Esko, J. D. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38251 · Cited by 226 · cited 12×
“Already in the early 1970s Zilversmit proposed that TRLs and remnants accumulate at arterial foci in proportion to the local concentrations of sulfated polysaccharides (21).”
BackgroundInfluentialXiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212 · cited 10×
“The hallmark of dyslipidemia in T2MD is high plasma triglycerides and low HDL-C.”
BackgroundInfluentialThe regulation of ApoB metabolism by insulin
Haas, M. E., Attie, A. D., & Biddinger, S. B. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.04.001 · Cited by 187 · cited 1×
“Furthermore, diabetes prevents clearance of TRLs by reducing hepatic uptake of apoB-containing lipoproteins, including RLPs (59), and by increasing levels of apoC3 through relative insulin deficiency or perhaps hepatic insulin resistance (17).”
BackgroundCampos, E., Nakajima, K., Tanaka, A., & Havel, R. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41527-5 · Cited by 182
Pechlaner, R., Tsimikas, S., Yin, X., Willeit, P., Baig, F., Santer, P., Oberhollenzer, F., Egger, G., Witztum, J. L., Alexander, V. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.065 · Cited by 171 · cited 9×
“With diabetic ketoacidosis, absolute insulin deficiency results in hypertriglyceridemia with low HDL-C and LDL-C levels (56).”
InfluentialLipid disorders in type 1 diabetes
Vergès, B. L. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.04.004 · Cited by 170 · cited 1×
“With diabetic ketoacidosis, absolute insulin deficiency results in hypertriglyceridemia with low HDL-C and LDL-C levels (56).”
BackgroundBerberich, A. J., & Hegele, R. A. (2013) · Nutrients · doi:10.3390/nu5030981 · Cited by 159
Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages.
Lenten, B. J. V., Fogelman, A. M., Jackson, R. L., Shapiro, S., Haberland, M. E., & Edwards, P. A. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39420-6 · Cited by 130 · cited 2×
“In contrast to unmodified LDL, native RLPs promote rapid cholesterol accumulation by macrophages (52,53), suggesting that RLPs are much more potent on a per particle basis than LDL at producing macrophage foam cells in vivo.”
BackgroundLaatsch, A., Merkel, M., Talmud, P. J., Grewal, T., Beisiegel†, U., & Heeren, J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.046 · Cited by 111 · cited 12×
“Already in the early 1970s Zilversmit proposed that TRLs and remnants accumulate at arterial foci in proportion to the local concentrations of sulfated polysaccharides (21).”
BackgroundInfluentialIncreased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes
Kanter, J. E., Shao, B., Kramer, F., Barnhart, S., Shimizu‐Albergine, M., Vaisar, T., Graham, M. J., Crooke, R. M., Manuel, C. R., Haeusler, R. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127308 · Cited by 111 · cited 14×
“With diabetic ketoacidosis, absolute insulin deficiency results in hypertriglyceridemia with low HDL-C and LDL-C levels (56).”
BackgroundInfluentialSelf-citationLeary, E. T., Wang, T., Baker, D. J., Cilla, D. D., Zhong, J., Warnick, G. R., Nakajima, K., & Havel, R. J. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.12.2490 · Cited by 110 · cited 2×
“Furthermore, macrophage uptake of RLPs from diabetic patients, isolated by immunoaffinity gel using the method described above (33) followed by ultracentrifugation, correlated with the degree of glycemic control in those subjects (67).”
BackgroundMethodFamilial dysbetalipoproteinemia: An underdiagnosed lipid disorder
Koopal, C., Marais, A. D., & Visseren, F. L. J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000316 · Cited by 101 · cited 1×
“RLP accumulation results when the APOE2/2 genotype is accompanied by a second genetic or acquired defect that causes overproduction of VLDL such as obesity or diabetes (45,46), a decrease in RLP clearance, or a reduction in LDL receptor activity (e.”
BackgroundQuantification of HDL Particle Concentration by Calibrated Ion Mobility Analysis
Hutchins, P. M., Ronsein, G. E., Monette, J. S., Pamir, N., Wimberger, J., He, Y., Anantharamaiah, G. M., Kim, D. S., Ranchalis, J., Jarvik, G. P., et al. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.228114 · Cited by 92 · cited 1×
“Differential Ion Mobility Differential ion mobility analysis can directly determine the size of a broad range of lipoprotein particles (39) and can be calibrated to provide information on particle concentrations and sizes (40).”
BackgroundSelf-citationNakajima, K., Nagamine, T., Fujita, M., Ai, M., Tanaka, A., & Schaefer, E. J. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800263-6.00003-3 · Cited by 89 · cited 1×
“Measurement of ApoB48 in Fasting Plasma Specific measurement of apoB48 in fasting plasma as distinct from apoB100 has been used as a measure of chylomicron remnants derived from the intestines (41).”
MethodMeasurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy
Otvos, J. D. (1999) · Clinical Cardiology · doi:10.1002/clc.4960221405 · Cited by 88 · cited 13×
“Measurement of RLPs by this immunoaffinity method correlates both with triglycerides in the combined VLDL and IDL ultracentrifugal fractions and with RLPs determined electrophoretically.”
MethodInfluentialPresence of multiple subpopulations of lipoproteins of intermediate density in normal subjects
Musliner, T. A., Giotas, C., & Krauss, R. M. (1986) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.6.1.79 · Cited by 87 · cited 2×
“Ultracentrifugation RLPs often are assessed by ultracentrifugation (29), which relies on relative flotation based on density.”
BackgroundTYPE-III HYPERLIPOPROTEINÆMIA ("REMNANT REMOVAL DISEASE")
Chait, A., Albers, J. J., Brunzell, J. D., & Hazzard, W. R. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92717-9 · Cited by 85
Self-citationUptake of Remnant Like Particles (RLP) in Diabetic Patients from Mouse Peritoneal Macrophages
Tomono, S., Kawazu, S., Kato, N., Ono, T., Ishii, C., Ito, Y., Shimizu, M., Shimoyama, M., Nakano, T., & Nakajima, K. (1994) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.1.98 · Cited by 76 · cited 1×
“Furthermore, macrophage uptake of RLPs from diabetic patients, isolated by immunoaffinity gel using the method described above (33) followed by ultracentrifugation, correlated with the degree of glycemic control in those subjects (67).”
MethodBalling, M., Langsted, A., Afzal, S., Varbo, A., Smith, G. D., & Nordestgaard, B. G. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.05.011 · Cited by 73
Redgrave, T. G., & Snibson, D. A. (1977) · Metabolism · doi:10.1016/0026-0495(77)90093-2 · Cited by 66 · cited 1×
“Some early studies in diabetic rats injected with radiolabeled chylomicrons demonstrated the accumulation of the cholesteryl ester but not the triglyceride components in plasma, suggesting that chylomicron-derived RLPs accumulate in diabetes (63).”
BackgroundChait, A., Hazzard, W. R., Albers, J. J., Kushwaha, R. P., & Brunzell, J. D. (1978) · Metabolism · doi:10.1016/0026-0495(78)90151-8 · Cited by 65 · cited 1×
“Interestingly, the reduced uptake of RLPs by the liver results not only in accumulation of RLPs but also, for unclear reasons, in reduced conversion of VLDL and IDL to LDL (27,48).”
BackgroundSelf-citationWhitman, S. C., Miller, D. B., Wolfe, B. M., Hegele, R. A., & Huff, M. W. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.9.1707 · Cited by 59 · cited 1×
“In contrast to unmodified LDL, native RLPs promote rapid cholesterol accumulation by macrophages (52,53), suggesting that RLPs are much more potent on a per particle basis than LDL at producing macrophage foam cells in vivo.”
BackgroundTriglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 59 · cited 2×
“Furthermore, clinical trials of fibrates and n-3 fatty acids (polyunsaturated fatty acids, also often referred to as fish oils) have, with the exception of REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) and JELIS (Japan EPA Lipid Intervention Study), been mostly negative for CVD…”
BackgroundKoopal, C., Retterstøl, K., Sjouke, B., Hovingh, G. K., Ros, E., de Graaf, J., Dullaart, R. P. F., Bertolini, S., & Visseren, F. L. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.046 · Cited by 58 · cited 2×
“The high prevalence of premature coronary artery disease (43,44) in remnant removal disease is strongly supportive of a direct role for RLPs in atherogenesis.”
BackgroundDevelopment of a Homogeneous Assay to Measure Remnant Lipoprotein Cholesterol
Miyauchi, K., Kayahara, N., Ishigami, M., Kuwata, H., Mori, H., Sugiuchi, H., Irie, T., Tanaka, A., Yamashita, S., & Yamamura, T. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.092296 · Cited by 56 · cited 1×
“Although ELISAs have been developed for RLP measurements (35), the validity of these ELISAs has been questioned (36).”
BackgroundAbnormal lipid composition of chylomicrons in broad-β disease (type III hyperlipoproteinemia)
Hazzard, W. R., Porte, D., & Bierman, E. L. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106403 · Cited by 51
Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.
Sprecher, D. L., Knauer, S. L., Black, D. M., Kaplan, L. A., Akeson, A. A., Dusing, M. R., Lattier, D. L., Stein, E. A., Rymaszewski, M., & Wiginton, D. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115402 · Cited by 49 · cited 1×
“Heterozygous deficiency of LPL leads to greater postprandial lipemia including the accumulation of more IDLs (19) and chylomicron remnants (20), whereas total LPL deficiency actually prevents the formation of RLPs (21).”
BackgroundDane-Stewart, C. A., Watts, G. F., Barrett, P. H. R., Stuckey, B. G. A., Mamo, J. C. L., Martins, I. J., & Redgrave, T. G. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01731.x · Cited by 42 · cited 1×
“Accordingly, in postmenopausal women, diabetes has been shown to decrease the catabolism of chylomicron-derived RLPs, resulting in accumulation of RLPs in plasma (62).”
BackgroundMoon, B. C., Hernández‐Ono, A., Stiles, B. L., Wu, H., & Ginsberg, H. N. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241356 · Cited by 41 · cited 1×
“The increased VLDL secretion is regulated largely by increased hepatic triglycerides rather than by chronically increased insulin signaling (58).”
BackgroundSelf-citationAtherogenic lipoproteins and diabetes mellitus
Yoshino, G., Hirano, T., & Kazumi, T. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00199-4 · Cited by 38 · cited 1×
“in T2DM independent of the presence of dyslipidemia (57).”
BackgroundKoopal, C., Geerlings, M. I., Muller, M., de Borst, G. J., Algra, A., van der Graaf, Y., & Visseren, F. L. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.009 · Cited by 35
Basu, A., Bebu, I., Jenkins, A. J., Stoner, J. A., Zhang, Y., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., Budoff, M. J., Alaupovic, P., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p090647 · Cited by 32 · cited 11×
“The major differences in lipid and lipoprotein profiles between T1DM and T2DM have previously been reviewed (54).”
BackgroundMethodInfluentialArterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats
Proctor, S. D., Pabla, C. K., & Mamo, J. C. L. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00341-x · Cited by 29 · cited 1×
“These findings are consistent with those of a subsequent study showing that retention of injected radiolabeled chylomicron remnants by the arterial intima in diabetic rabbits and rats correlated with hyperglycemia due to insulin deficiency (66).”
ResultApolipoprotein E-Containing Lipoproteins and Lipoprotein Remnants in Experimental Canine Diabetes
Wilson, D. E., Chan, I. F., Elstad, N. L., Peric‐Golia, L., Hejazi, J., Albu, D. S., & Cutfield, R. G. (1986) · Diabetes · doi:10.2337/diab.35.8.933 · Cited by 19
LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes
Murdoch, S. J., Boright, A. P., Paterson, A. D., Zinman, B., Steffes, M. W., Cleary, P. A., Edwards, K. L., Marcovina, S., Purnell, J. Q., & Brunzell, J. D. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.04.023 · Cited by 18
Ooi, E. M. M., Russell, B. S., Olson, E., Sun, S. Z., Diffenderfer, M. R., Lichtenstein, A. H., Keilson, L., Barrett, P. H. R., Schaefer, E. J., & Sprecher, D. L. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.238493 · Cited by 17 · cited 2×
“Residual CVD risk appears to be at least partly linked to elevated plasma triglycerides and abnormal metabolism of triglyceride-rich lipoproteins (TRLs) (6,7), which are conventionally considered to consist of chylomicrons, VLDLs, and their respective remnant lipoproteins (remnant lipoprotein particles [RLPs]), many o…”
BackgroundNakajima, K., Tokita, Y., Sakamaki, K., Shimomura, Y., Kobayashi, J., Kamachi, K., Tanaka, A., Stanhope, K. L., Havel, P. J., Wang, T., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.12.011 · Cited by 17 · cited 1×
“Changes in RLP cholesterol determined by this immunoaffinity method also correlate highly with increment in triglycerides postprandially (34).”
MethodFeussner, G., & Ziegler, R. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00428.x · Cited by 16
Chylomicron and Chylomicron Remnant Metabolism in STZ-Induced Diabetic Rats
Staprãns, I., Pan, X.-M., Rapp, J. H., & Feingold, K. R. (1992) · Diabetes · doi:10.2337/diab.41.3.325 · Cited by 15 · cited 1×
“How could RLPs accelerate CVD in the setting of diabetes? Early studies identified increased binding of chylomicrons/chylomicron remnants to the artery wall despite a lack of detectable accumulation of RLPs in plasma (65).”
BackgroundSubramanian, S., & Chait, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65798-7 · Cited by 9
Self-citationA New Start for Triglycerides and Remnant Cholesterol—Nonfasting
Nordestgaard, B. G. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.268938 · Cited by 8 · cited 1×
“Subtraction Method Another method used as a simple approximation of RLPs in nonfasting plasma relies on calculating the sum of VLDL, IDL, and chylomicron cholesterol, using the formula RLP 5 total cholesterol 2 HDL-C 2 LDL-C, but requires specific isolation of LDL by ultracentrifugation (42).”
MethodEvaluation of the classical methods for the diagnosis of type III hyperlipoproteinemia
Patsch, J. R., Jackson, R. L., & Gotto, A. M. (1977) · Journal of Molecular Medicine · doi:10.1007/bf01489475 · Cited by 7 · cited 1×
“Plasma from individuals with remnant removal disease exhibit a broad band of material that migrates between b-lipoproteins (LDL) and pre-b-lipoproteins (VLDL) on electrophoresis (30).”
BackgroundLimitations of Automated Remnant Lipoprotein Cholesterol Assay for Diagnostic Use
Schaefer, E. J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.133934 · Cited by 6
Research works printed but not linked: 1
- Mahley, 1989, Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 1195
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“Very low-density lipoproteins (VLDL), made in the liver, contain apoB100 and are metabolized to VLDL remnants, intermediate-density lipoproteins (IDL), and LDL. Chylomicrons, made in the intestine, are larger and contain apoB48, and are also metabolized to remnant particles but not to IDL and LDL ( Figure 1 ).”
BackgroundInfluentialSelf-citationThe Role of Inflammation in Cardiovascular Disease
Henein, M. Y., Vancheri, S., Longo, G., & Vancheri, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112906 · Cited by 724
2023 Chinese guideline for lipid management
Li, J.-J., Zhao, S.-P., Zhao, D., Lu, G.-P., Peng, D.-Q., Liu, J., Chen, Z.-Y., Guo, Y.-L., Wu, N.-Q., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 223
Management of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 223
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K. E., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 212
Self-citation
Metadata
- Authors
- Chait, A., Ginsberg, H. N., Vaisar, T., Heinecke, J. W., Goldberg, I. J., & Bornfeldt, K. E.
- Affiliations
- University of Washington (US)
- Columbia University (US)
- Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA
- New York University (US)
- Corresponding author
- Bornfeldt, Karin E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-16
- Volume
- 69
- Issue
- 4
- Pages
- 508-516
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC7085249
- OpenAlex
- W3011963422
- Cited by
- 229
- References
- 72
- Citations by year
- 2026: 26 · 2025: 36 · 2024: 49 · 2023: 46 · 2022: 38 · 2021: 21 · 2020: 13
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL126028, R01HL127694, P01HL092969, R01HL45095, R01HL73029, P01HL128203, R01HL144558, R35HL135833)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK017047, DP3DK108209)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- remnant lipoproteins, triglyceride-rich lipoproteins, atherosclerotic cardiovascular disease, residual cardiovascular risk, prediabetes, apolipoprotein E, apolipoprotein B-48, apolipoprotein B-100, chylomicrons, VLDL, lipolysis, atherosclerosis
- MeSH terms
- Animals, Cardiovascular Diseases, Chylomicrons, Diabetes Mellitus, Type 2, Humans, Lipoproteins, Lipoproteins, VLDL, Triglycerides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.